BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23918374)

  • 1. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
    Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; LeKaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):E3506-15. PubMed ID: 23918374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation.
    Selvaraj N; Budka JA; Ferris MW; Jerde TJ; Hollenhorst PC
    Mol Cancer; 2014 Mar; 13():61. PubMed ID: 24642271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer.
    Liu CY; Yu T; Huang Y; Cui L; Hong W
    J Biol Chem; 2017 Jun; 292(22):9420-9430. PubMed ID: 28408625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
    Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
    Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.
    Oh S; Shin S; Janknecht R
    Biochim Biophys Acta; 2012 Aug; 1826(1):1-12. PubMed ID: 22425584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
    Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
    Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis.
    Baker SJ; Reddy EP
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14819-20. PubMed ID: 23995446
    [No Abstract]   [Full Text] [Related]  

  • 9. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
    Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
    Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.
    Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM
    Cancer Res; 2013 Jul; 73(14):4533-47. PubMed ID: 23687337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
    Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
    Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
    Barros-Silva JD; Paulo P; Bakken AC; Cerveira N; Løvf M; Henrique R; Jerónimo C; Lothe RA; Skotheim RI; Teixeira MR
    Neoplasia; 2013 Jul; 15(7):720-6. PubMed ID: 23814484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of novel ETV4 splice variants in prostate cancer.
    Cosi I; Moccia A; Pescucci C; Munagala U; Di Giorgio S; Sineo I; Conticello SG; Notaro R; De Angioletti M
    Sci Rep; 2023 Mar; 13(1):5267. PubMed ID: 37002241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control.
    DeSalvo J; Ban Y; Li L; Sun X; Jiang Z; Kerr DA; Khanlari M; Boulina M; Capecchi MR; Partanen JM; Chen L; Kondo T; Ornitz DM; Trent JC; Eid JE
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 33983905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ETV4 is a theranostic target in clear cell renal cell carcinoma that promotes metastasis by activating the pro-metastatic gene FOSL1 in a PI3K-AKT dependent manner.
    Xu L; Hu H; Zheng LS; Wang MY; Mei Y; Peng LX; Qiang YY; Li CZ; Meng DF; Wang MD; Liu ZJ; Li XJ; Huang BJ; Qian CN
    Cancer Lett; 2020 Jul; 482():74-89. PubMed ID: 32305558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
    Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
    J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of ETV4 at Ser73 by ERK kinase could block ETV4 ubiquitination degradation in colorectal cancer.
    Xiao J; Yang S; Shen P; Wang Y; Sun H; Ji F; Zhou D
    Biochem Biophys Res Commun; 2017 May; 486(4):1062-1068. PubMed ID: 28373072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling.
    Wollenick K; Hu J; Kristiansen G; Schraml P; Rehrauer H; Berchner-Pfannschmidt U; Fandrey J; Wenger RH; Stiehl DP
    Nucleic Acids Res; 2012 Mar; 40(5):1928-43. PubMed ID: 22075993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
    Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
    Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.